https://insights.citeline.comMon, 04 Nov 2024 10:15:48 +0000en1hourly1https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-biogen-gets-new-chief-medical-officer-from-bms-3LHJY5GYZVGJFFLZH4BNAA6T5E/https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-biogen-gets-new-chief-medical-officer-from-bms-3LHJY5GYZVGJFFLZH4BNAA6T5E/Fri, 01 Nov 2024 12:32:47 +0000https://insights.citeline.com/medtech-insight/conferences/hlth-2024-ge-healthcares-chief-ai-officer-says-future-of-ai-no-longer-a-black-box-ZKVIB4TLFRAF5IEHSV6ADZ3KS4/https://insights.citeline.com/medtech-insight/conferences/hlth-2024-ge-healthcares-chief-ai-officer-says-future-of-ai-no-longer-a-black-box-ZKVIB4TLFRAF5IEHSV6ADZ3KS4/Fri, 01 Nov 2024 19:30:11 +0000GE Healthhttps://insights.citeline.com/medtech-insight/business/r-and-d/news-were-watching-histosonics-secures-90m-va-deal-crc-blood-test-deemed-less-cost-effectiveness-more-6D3IWGMMMVBJXOD7W7BVACSJ4E/https://insights.citeline.com/medtech-insight/business/r-and-d/news-were-watching-histosonics-secures-90m-va-deal-crc-blood-test-deemed-less-cost-effectiveness-more-6D3IWGMMMVBJXOD7W7BVACSJ4E/Fri, 01 Nov 2024 23:46:12 +0000https://insights.citeline.com/pink-sheet/agency-leadership/ema/new-ema-fees-could-shake-up-pharma-submission-strategies-UJYLQHQJJRD35I7OAOBSHMQIQQ/https://insights.citeline.com/pink-sheet/agency-leadership/ema/new-ema-fees-could-shake-up-pharma-submission-strategies-UJYLQHQJJRD35I7OAOBSHMQIQQ/Fri, 01 Nov 2024 15:35:16 +0000https://insights.citeline.com/pink-sheet/biosimilars-and-generics/teva-fined-half-a-billion-dollars-over-european-copaxone-antitrust-breach-YEJ7BD5XM5DDBAEB4QH7LDS5ZQ/https://insights.citeline.com/pink-sheet/biosimilars-and-generics/teva-fined-half-a-billion-dollars-over-european-copaxone-antitrust-breach-YEJ7BD5XM5DDBAEB4QH7LDS5ZQ/Fri, 01 Nov 2024 15:45:57 +0000https://insights.citeline.com/pink-sheet/geography/europe/ema-seeks-feedback-on-coi-policy-changes-following-legal-rulings-FYQ74YWPCBDBFM3ZX3YFZAWAZQ/https://insights.citeline.com/pink-sheet/geography/europe/ema-seeks-feedback-on-coi-policy-changes-following-legal-rulings-FYQ74YWPCBDBFM3ZX3YFZAWAZQ/Fri, 01 Nov 2024 15:05:58 +0000https://insights.citeline.com/pink-sheet/legislation/elections/the-rfk-wild-card-uncertainty-for-us-fda-in-a-second-trump-term-VHBC3BHFGJBTVIANPFE3ZPNIKQ/https://insights.citeline.com/pink-sheet/legislation/elections/the-rfk-wild-card-uncertainty-for-us-fda-in-a-second-trump-term-VHBC3BHFGJBTVIANPFE3ZPNIKQ/Fri, 01 Nov 2024 17:56:30 +0000https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-new-rare-disease-hub-director-rick-brings-advocacy-experience-QDFWZWICV5DM5IZUTVFIVQZLBQ/https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-new-rare-disease-hub-director-rick-brings-advocacy-experience-QDFWZWICV5DM5IZUTVFIVQZLBQ/Sat, 02 Nov 2024 02:05:00 +0000https://insights.citeline.com/pink-sheet/rare-diseases/practical-matters-rare-disease-advocates-want-help-from-us-fda-hub-to-make-data-useful-WCTRXKH5SFD3HIPZG62CA2TIAA/https://insights.citeline.com/pink-sheet/rare-diseases/practical-matters-rare-disease-advocates-want-help-from-us-fda-hub-to-make-data-useful-WCTRXKH5SFD3HIPZG62CA2TIAA/Sat, 02 Nov 2024 02:02:00 +0000https://insights.citeline.com/medtech-insight/geography/europe/united-kingdom/medtechs-applaud-uk-life-sciences-fund-but-seek-lowering-of-8m-project-threshold-26MYD2TG65FL7CADK4J53GCVMI/https://insights.citeline.com/medtech-insight/geography/europe/united-kingdom/medtechs-applaud-uk-life-sciences-fund-but-seek-lowering-of-8m-project-threshold-26MYD2TG65FL7CADK4J53GCVMI/Sat, 02 Nov 2024 10:58:08 +0000https://insights.citeline.com/scrip/business/financing/sage-prioritizes-zurzuvae-for-ppd-ends-mdd-effort-drops-zulresso-4L4OID2T6FDYDNFDWUI5PRTOYM/https://insights.citeline.com/scrip/business/financing/sage-prioritizes-zurzuvae-for-ppd-ends-mdd-effort-drops-zulresso-4L4OID2T6FDYDNFDWUI5PRTOYM/Sat, 02 Nov 2024 03:18:11 +0000https://insights.citeline.com/companies/evofem-biosciences-inchttps://insights.citeline.com/companies/evofem-biosciences-incSat, 02 Nov 2024 00:03:34 +0000https://insights.citeline.com/companies/vertos-medical-inchttps://insights.citeline.com/companies/vertos-medical-incSat, 02 Nov 2024 00:03:31 +0000https://insights.citeline.com/companies/saptalis-pharmaceuticals-llchttps://insights.citeline.com/companies/saptalis-pharmaceuticals-llcSat, 02 Nov 2024 00:03:28 +0000https://insights.citeline.com/companies/jenavalve-technology-inchttps://insights.citeline.com/companies/jenavalve-technology-incSat, 02 Nov 2024 00:03:25 +0000https://insights.citeline.com/companies/relief-therapeutics-holding-aghttps://insights.citeline.com/companies/relief-therapeutics-holding-agSat, 02 Nov 2024 00:03:22 +0000https://insights.citeline.com/companies/zoll-medical-corphttps://insights.citeline.com/companies/zoll-medical-corpSat, 02 Nov 2024 00:03:19 +0000https://insights.citeline.com/companies/mirror-biologicshttps://insights.citeline.com/companies/mirror-biologicsSat, 02 Nov 2024 00:03:16 +0000https://insights.citeline.com/companies/autonomous-therapeutics-inchttps://insights.citeline.com/companies/autonomous-therapeutics-incSat, 02 Nov 2024 00:03:13 +0000https://insights.citeline.com/companies/shockwave-medical-inchttps://insights.citeline.com/companies/shockwave-medical-incSat, 02 Nov 2024 00:03:10 +0000https://insights.citeline.com/companies/amorphical-ltdhttps://insights.citeline.com/companies/amorphical-ltdSat, 02 Nov 2024 00:03:07 +0000https://insights.citeline.com/companies/ocuvex-therapeuticshttps://insights.citeline.com/companies/ocuvex-therapeuticsSat, 02 Nov 2024 00:03:04 +0000https://insights.citeline.com/companies/nodus-oncologyhttps://insights.citeline.com/companies/nodus-oncologySat, 02 Nov 2024 00:03:01 +0000https://insights.citeline.com/companies/aliada-therapeuticshttps://insights.citeline.com/companies/aliada-therapeuticsSat, 02 Nov 2024 00:02:55 +0000https://insights.citeline.com/companies/kynos-therapeutics-ltdhttps://insights.citeline.com/companies/kynos-therapeutics-ltdSat, 02 Nov 2024 00:02:52 +0000https://insights.citeline.com/companies/aditxt-inchttps://insights.citeline.com/companies/aditxt-incSat, 02 Nov 2024 00:02:49 +0000https://insights.citeline.com/companies/tnf-pharmaceuticals-inchttps://insights.citeline.com/companies/tnf-pharmaceuticals-incSat, 02 Nov 2024 00:02:46 +0000https://insights.citeline.com/companies/inbrain-neuroelectronicshttps://insights.citeline.com/companies/inbrain-neuroelectronicsSat, 02 Nov 2024 00:02:42 +0000https://insights.citeline.com/companies/curi-bio-inchttps://insights.citeline.com/companies/curi-bio-incSat, 02 Nov 2024 00:02:39 +0000https://insights.citeline.com/companies/immunovative-therapies-ltdhttps://insights.citeline.com/companies/immunovative-therapies-ltdSat, 02 Nov 2024 00:02:37 +0000https://insights.citeline.com/companies/zhejiang-pukang-biotechnology-co-ltdhttps://insights.citeline.com/companies/zhejiang-pukang-biotechnology-co-ltdSat, 02 Nov 2024 00:02:34 +0000https://insights.citeline.com/companies/essilorluxotticahttps://insights.citeline.com/companies/essilorluxotticaSat, 02 Nov 2024 00:02:31 +0000https://insights.citeline.com/companies/appili-therapeutics-inchttps://insights.citeline.com/companies/appili-therapeutics-incSat, 02 Nov 2024 00:02:27 +0000https://insights.citeline.com/companies/nissan-chemical-corporationhttps://insights.citeline.com/companies/nissan-chemical-corporationSat, 02 Nov 2024 00:02:24 +0000https://insights.citeline.com/companies/immunovia-abhttps://insights.citeline.com/companies/immunovia-abSat, 02 Nov 2024 00:02:18 +0000https://insights.citeline.com/companies/vyaire-medical-inchttps://insights.citeline.com/companies/vyaire-medical-incSat, 02 Nov 2024 00:02:15 +0000https://insights.citeline.com/companies/amolyt-pharmahttps://insights.citeline.com/companies/amolyt-pharmaSat, 02 Nov 2024 00:02:09 +0000https://insights.citeline.com/companies/v-wave-ltdhttps://insights.citeline.com/companies/v-wave-ltdSat, 02 Nov 2024 00:02:06 +0000https://insights.citeline.com/companies/nordson-corporationhttps://insights.citeline.com/companies/nordson-corporationSat, 02 Nov 2024 00:02:03 +0000https://insights.citeline.com/companies/grail-inchttps://insights.citeline.com/companies/grail-incSat, 02 Nov 2024 00:02:00 +0000https://insights.citeline.com/companies/masimo-corphttps://insights.citeline.com/companies/masimo-corpSat, 02 Nov 2024 00:01:57 +0000https://insights.citeline.com/companies/kintara-therapeuticshttps://insights.citeline.com/companies/kintara-therapeuticsSat, 02 Nov 2024 00:01:54 +0000https://insights.citeline.com/companies/johnson-johnsonhttps://insights.citeline.com/companies/johnson-johnsonSat, 02 Nov 2024 00:01:51 +0000https://insights.citeline.com/companies/ucb-sahttps://insights.citeline.com/companies/ucb-saSat, 02 Nov 2024 00:01:48 +0000https://insights.citeline.com/companies/abbvie-inchttps://insights.citeline.com/companies/abbvie-incSat, 02 Nov 2024 00:01:45 +0000https://insights.citeline.com/companies/merck-co-inchttps://insights.citeline.com/companies/merck-co-incSat, 02 Nov 2024 00:01:45 +0000https://insights.citeline.com/companies/dr-falk-pharma-gmbhhttps://insights.citeline.com/companies/dr-falk-pharma-gmbhSat, 02 Nov 2024 00:01:36 +0000https://insights.citeline.com/companies/roche-holding-aghttps://insights.citeline.com/companies/roche-holding-agSat, 02 Nov 2024 00:01:30 +0000https://insights.citeline.com/companies/eli-lilly-and-companyhttps://insights.citeline.com/companies/eli-lilly-and-companySat, 02 Nov 2024 00:01:24 +0000https://insights.citeline.com/companies/lipomedix-pharmaceuticalshttps://insights.citeline.com/companies/lipomedix-pharmaceuticalsSat, 02 Nov 2024 00:01:18 +0000https://insights.citeline.com/companies/zydus-lifesciences-limitedhttps://insights.citeline.com/companies/zydus-lifesciences-limitedSat, 02 Nov 2024 00:01:12 +0000https://insights.citeline.com/companies/indivior-plchttps://insights.citeline.com/companies/indivior-plcSat, 02 Nov 2024 00:01:06 +0000https://insights.citeline.com/companies/arca-biopharma-inchttps://insights.citeline.com/companies/arca-biopharma-incSat, 02 Nov 2024 00:01:00 +0000https://insights.citeline.com/companies/grunenthal-gmbhhttps://insights.citeline.com/companies/grunenthal-gmbhSat, 02 Nov 2024 00:00:54 +0000https://insights.citeline.com/companies/astrazeneca-plchttps://insights.citeline.com/companies/astrazeneca-plcSat, 02 Nov 2024 00:00:41 +0000https://insights.citeline.com/scrip/r-and-d/clinical-trials/novo-nordisks-semaglutide-hits-phase-iii-marks-in-nash-CBI3UXYJFZDZVI4CDLTMQEU3DE/https://insights.citeline.com/scrip/r-and-d/clinical-trials/novo-nordisks-semaglutide-hits-phase-iii-marks-in-nash-CBI3UXYJFZDZVI4CDLTMQEU3DE/Fri, 01 Nov 2024 22:06:05 +0000https://insights.citeline.com/scrip/r-and-d/clinical-trials/ucb-weighs-up-alzheimers-drug-future-after-phase-ii-miss-and-roche-exit-XIWAX7VJZZEDRMM6IUV4KGURAA/https://insights.citeline.com/scrip/r-and-d/clinical-trials/ucb-weighs-up-alzheimers-drug-future-after-phase-ii-miss-and-roche-exit-XIWAX7VJZZEDRMM6IUV4KGURAA/Fri, 01 Nov 2024 17:09:24 +0000https://insights.citeline.com/scrip/business/earnings/compass-antidepression-psychedelic-still-on-course-despite-delays-WII3XPIUQ5CQTCJBYVSSYPD4MM/https://insights.citeline.com/scrip/business/earnings/compass-antidepression-psychedelic-still-on-course-despite-delays-WII3XPIUQ5CQTCJBYVSSYPD4MM/Fri, 01 Nov 2024 16:01:27 +0000https://insights.citeline.com/scrip/business/start-ups-and-smes/emerging-company-profiles/volastra-aims-to-terminate-cancer-relying-on-chromosomal-instability-HLWAE2QJ2FFFLLSANKXMTTCTGU/https://insights.citeline.com/scrip/business/start-ups-and-smes/emerging-company-profiles/volastra-aims-to-terminate-cancer-relying-on-chromosomal-instability-HLWAE2QJ2FFFLLSANKXMTTCTGU/Fri, 01 Nov 2024 21:43:10 +0000https://insights.citeline.com/hbw-insight/wellness/business/earnings/more-herbalife-distributors-more-for-them-to-do-WGCZ5IIGT5DKBHIIVUQ3X5XNIY/https://insights.citeline.com/hbw-insight/wellness/business/earnings/more-herbalife-distributors-more-for-them-to-do-WGCZ5IIGT5DKBHIIVUQ3X5XNIY/Fri, 01 Nov 2024 21:40:14 +0000https://insights.citeline.com/hbw-insight/health/business/earnings/bausch-lomb-results-enhance-acquisition-image-74TT2U5645F5NMP6F3JGNXZH2I/https://insights.citeline.com/hbw-insight/health/business/earnings/bausch-lomb-results-enhance-acquisition-image-74TT2U5645F5NMP6F3JGNXZH2I/Fri, 01 Nov 2024 21:39:49 +0000https://insights.citeline.com/hbw-insight/geography/asia/china/haleon-talks-up-china-strength-as-investment-grows-ANWZGYGFOZHRPB23ATTOWLVQLA/https://insights.citeline.com/hbw-insight/geography/asia/china/haleon-talks-up-china-strength-as-investment-grows-ANWZGYGFOZHRPB23ATTOWLVQLA/Fri, 01 Nov 2024 16:13:06 +0000https://insights.citeline.com/generics-bulletin/business/strategy/brazils-hypera-unanimously-rejects-ems-proposed-merger-CGB26QJRBBAVTD47WL3GARHHG4/https://insights.citeline.com/generics-bulletin/business/strategy/brazils-hypera-unanimously-rejects-ems-proposed-merger-CGB26QJRBBAVTD47WL3GARHHG4/Fri, 01 Nov 2024 12:22:05 +0000https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda-floats-communications-upgrade-for-andas-with-missed-goals-Z67UM23UJZDJ3GCEXHZ24W6Q3E/https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/us-fda-floats-communications-upgrade-for-andas-with-missed-goals-Z67UM23UJZDJ3GCEXHZ24W6Q3E/Fri, 01 Nov 2024 12:02:34 +0000https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/product-or-class-guidances-for-biosimilars-industry-had-its-say-PO57RBWGWBB3ZDTBUYMXLJFELQ/https://insights.citeline.com/generics-bulletin/policy-and-regulation/regulation/product-or-class-guidances-for-biosimilars-industry-had-its-say-PO57RBWGWBB3ZDTBUYMXLJFELQ/Fri, 01 Nov 2024 12:00:24 +0000